Mind Medicine (MindMed) Inc. - Common Shares (NQ:MNMD)

15.02 UNCHANGED

Last Price Updated: 4:00 PM EST, Jan 14, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Mind Medicine (MindMed) Inc. - Common Shares

< Previous 1 2

...

28 29 30 31 32 33 34 35 Next >

Behind the Wall: Psychedelics Have “Absolutely Transformational” Potential ↗

November 11, 2021

Is now the time to invest in psychedelic stocks? Dustin Robinson, founder of venture capital firm Iter Investments, says yes and explains why.

Via InvestorPlace

Compass Pathways Goes On Bad Trip, Despite 'Positive' Results From Psilocybin Trial ↗

November 09, 2021

Shares plunged, despite a psilocybin-based drug reducing depression in a trial.

Via Investor's Business Daily

This Could Be The Next Multi-Billion AI Breakthrough

November 05, 2021

FN Media Group Presents GlobalInvestmentDaily.com Market Commentary London – November 5, 2021 – There’s a massive announcement set to take place later this year, and it could change the $12 trillion...

Via FinancialNewsMedia

Topics Artificial Intelligence

Compass Pathways 2.0: A New Rally In Psychedelic Stocks? ↗

November 04, 2021

Compass Pathways' IPO sparked a sector-wide rally in 2020. Now CMPS is on the move again. Is history about to repeat?

Via Talk Markets

Topics Initial Public Offering

Psychedelics Offer Hope for Mental Disorders, Addiction

November 03, 2021

Via Investor Brand Network

How This Company Is Using Psychedelic Medicines and Therapies to Treat Addiction and Mental Illness ↗

November 02, 2021

Courtesy of: MindMed The following post was written and/or published as a collaboration between Benzinga’s in-house sponsored c...

Via Benzinga

Magic Mushrooms and Ecstasy: New Treatment For Autism Spectrum Disorders? ↗

November 01, 2021

Much like cannabis, psychedelics are catch...

Via Benzinga

Topics Cannabis

Psyched: MindMed's MDMA Program For Autism, Small Pharma's New Patent, NovaMentis' Orphan Drug Designation ↗

November 01, 2021

The Week In Psychedelics:

Via Benzinga

Topics Intellectual Property

Developments with Ketamine Psychotherapy Are Driving A Medical Revolution For Treating Mental Health Issues

October 28, 2021

Palm Beach, FL –October 28, 2021 – FinancialNewsMedia.com News Commentary – Psychedelic drugs such as psilocybin, LSD and MDMA have tremendous medical and commercial future potential… and for ketamine,...

Via FinancialNewsMedia

Topics Death Law Enforcement

Biotech Companies Are Embracing the Growing Psychedelic Drug Market To Confront a Global Increase in Depression and Anxiety ↗

October 27, 2021

Image by 3D Animation Production Company from Pixabay The following post was written and/or published as a collaboration between Benzinga’s in-house sponsored content team...

Via Benzinga

North America Continues Leading The Way In Psychedelic Wellness

October 26, 2021

Palm Beach, FL –October 26, 2021 – FinancialNewsMedia.com News Commentary – The global psychedelic drugs market remains at an early stage in its life cycle, with most companies currently developing...

Via FinancialNewsMedia

Phase 2 Trial On Ayahuasca's Active Ingredient Puts Small Pharma On Track To Winning The Psychedelics Race ↗

October 20, 2021

Small Pharma Inc. (OTCQB:DMTTF) (TSXV:

Via Benzinga

Two Trillion-Dollar Industries Being Transformed By Tech

October 20, 2021

FN Media Group Presents Oilprice.com Market Commentary London – October 20, 2021 – Big money is pouring into two disruptive segments in two of the world’s biggest industries – healthcare and energy....

Via FinancialNewsMedia

Psyched: The 50 Publicly-listed Psychedelics Companies, Atai's New Subsidiary, PharmaTher Gets New Orphan Drug Designation ↗

October 18, 2021

The Week In Psychedelics

Via Benzinga

Forget The Hype: The Psychedelic Stocks Sector Went Down In The Third Quarter Of 2021 ↗

October 15, 2021

Despite the prevailing hype, the psychedelic sector went down considerably last quarter (July through September) and has gone down even further so far this month.

Via Talk Markets

Rising Acceptance For Treating Mental Disorders is Fueling Strong Growth in Psychedelic Drugs Market

October 14, 2021

Palm Beach, FL –October 14, 2021 – FinancialNewsMedia.com News Commentary – Mental disorders are an urgent health crisis worldwide, especially exacerbated by COVID-19. As per a study by Harvard, the...

Via FinancialNewsMedia

Psychedelic Stocks: Financial Strength, Growth Potential, Compelling Valuations ↗

October 12, 2021

Blue-chip stocks: grossly inflated valuations and loaded with debt. Psychedelic stocks: lean valuations and loaded with cash. A very attractive option in uncertain markets.

Via Talk Markets

Psyched: Seattle Decriminalizes Psychedelics, Psilocybin Increases Emotions From Music, Novamind's Palliative Care Program ↗

October 11, 2021

The Week In Psychedelics

Via Benzinga

There Are Now 50 Psychedelics Companies Listed In The U.S. - Here They Are ↗

October 13, 2021

Just two years ago, the psychedelics sector was a small research space reserved for academics and extremely forward-thinking investors. S...

Via Benzinga

Former Tilray CEO Joins Psychedelics Company ↗

October 07, 2021

More big names in cannabis are switching to psychedelics. Greg Engel, former CEO of Tilray (NASDAQ:

Via Benzinga

Topics Cannabis

MindMed Teams Up With Sphere Health To Identify Biomarkers Associated With Anxiety & Depression ↗

October 05, 2021

Psychedelic–focused biotech company Mind Medicine Inc. (NASDAQ: MNMD) (NEO: MMED) (DE: MMQ) disclosed on Tuesday that it has agreed to partner with Sphere Health to...

Via Benzinga

U.S. Is Dominating Psychedelic Drugs Market Due To Growing Acceptance For Treating Depression & Rise In Product Approvals

October 12, 2021

Palm Beach, FL –October 12, 2021 – FinancialNewsMedia.com News Commentary – After being relegated to the margins of sincere scientific examination for about the last several decades, growing...

Via FinancialNewsMedia

Cannabis Movers & Shakers: Leafly Holdings, Linneo Health, Flowhub, MindMed ↗

October 04, 2021

Leafly Holdings Taps Suresh Krishnaswamy As New CFO The cannabis information platform Leafly Holdings, Inc. recently disclosed ...

Via Benzinga

Topics Cannabis

Psychedelic Front Runners MindMed , BioXcel Patent System To Identify Agitation ↗

October 04, 2021

This article by Gaurav Dubey was originally published on

Via Benzinga

Topics Intellectual Property

COVID Tests, THC Patches, Psychedelics: Xphyto Therapeutics Does it All ↗

October 04, 2021

Image by Shameer Pk from Pixabay From 25-minute COVID-19 lab tests to psychedelic medicine that is poised to address mental health conditions like PTSD, XPhyto Therapeutics (...

Via Benzinga

6 Psychedelic Stocks With Buy Rating: Why Are They Good Investments? ↗

October 01, 2021

This article by Jason Najum was originally published on

Via Benzinga

NetworkNewsAudio – Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) Bringing Therapeutic Options to Diseases with Unmet Needs

September 30, 2021

Via Investor Brand Network

Topics Cannabis

Four Stocks Disrupting Mental Health To Keep An Eye On At Benzinga's Healthcare Conference ↗

September 30, 2021

The healthcare sector is booming and startups are the driving force behind the innovations that will affect the future of life on earth. ...

Via Benzinga

Digital Therapeutics And The Future Of Psychedelic Medicine ↗

September 29, 2021

Digital health and therapeutics will play a crucial role in the future of medicine. Across medical and mental health industries, companies are real...

Via Benzinga

Psychedelics Renaissance Underway as Paradigm Shifting Cure for Depression Potentially Discovered

September 28, 2021

Via FinancialNewsMedia

Topics Law Enforcement

< Previous 1 2

...

28 29 30 31 32 33 34 35 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.